Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin for Prevention of Colon Cancer in Smokers with ACF
NCT00365209Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2006
- Primary completion
- Sep 2008
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of curcumin in colon cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Prostaglandin E2 in Aberrant Crypt Foci at 30 days. Started Oct 2006; status: completed.
02
Drugs
curcumin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT00365209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365209.